Chlorodehydromethylandrostenediol
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| Identifiers | |
| |
| Synonyms | CDMA; Halodrol; Halodrol-50 |
| CAS Number | 1338221-84-3 |
| PubChem (CID) | 29976098 |
| ChemSpider | 29976098 |
| UNII | K6PH0FVE0K |
| Chemical and physical data | |
| Formula | C20H29ClO2 |
| Molar mass | 336.90 g·mol−1 |
| 3D model (Jmol) | Interactive image |
| |
| |
Chlorodehydromethylandrostenediol (CDMA), also known as 4-chloro-17α-methyl-androst-1,4-diene-3β,17β-diol, is a synthetic, orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of 4-androstenediol that was never marketed.[1] It was first encountered in 2005 when it was introduced as a "dietary supplement" and putative prohormone under the name Halodrol-50 by an online vendor called Gaspari Nutrition.[1][2] The drug was the subject of a scathing and highly critical article by the Washington Post in November 2006.[1] CDMA was voluntarily discontinued by Gaspari Nutrition in mid-2006, likely fearing government sanctions if it continued to sell the product.[1] During the brief period of time that CDMA was sold online, it was an extremely well-selling product; its total sales are estimated to have been in the tens of millions of dollars, and by some estimates, CDMA may have been the best-selling hormonal product ever sold "over-the-counter" (i.e., without a prescription) in the United States.[1]
Although CDMA was sold as a "prohormone" or "prosteroid" of chlorodehydromethyltestosterone (CDMT), it is likely that the conversion is far from complete and that much of the activity of the drug may be attributable to its unchanged form.[1] Due to the presence of a chloro group at the C4 position, CDMA cannot be aromatized, and for this reason, poses no risk of estrogenic side effects like gynecomastia at any dosage.[1] It is not extensively metabolized by 5α-reductase and exhibits relatively greater anabolic than androgenic activity, but is still capable of producing androgenic side effects like oily skin, acne, and increased growth of facial and body hair, as well as virilization in women.[1] As with other 17α-alkylated AAS, CDMA poses a risk of hepatotoxicity.[1][3]
CDMA is closely related to chloromethylandrostenediol (CMA; Promagnon), which was developed by the same person, Bruce Kneller, and was also briefly sold on the Internet in 2005 and 2006, though by a different company.[1] Both drugs were derived from CDMT (brand name Oral Turinabol), a popular AAS that was introduced in the 1960s.[1]
See also
References
- 1 2 3 4 5 6 7 8 9 10 11 12 William Llewellyn (1 November 2008). Anabolics: Anabolic Steroid Reference Guide. William Llewellyn. pp. 260,365. ISBN 978-0-9679304-7-3.
- ↑ Detlef Thieme; Peter Hemmersbach (18 December 2009). Doping in Sports. Springer Science & Business Media. pp. 179–. ISBN 978-3-540-79088-4.
- ↑ Kafrouni MI, Anders RA, Verma S (2007). "Hepatotoxicity associated with dietary supplements containing anabolic steroids". Clin. Gastroenterol. Hepatol. 5 (7): 809–12. doi:10.1016/j.cgh.2007.02.036. PMID 17509944.